| age |
67 (11) |
| gender |
|
| Female |
15 / 34 (44%) |
| Male |
19 / 34 (56%) |
| SBP |
148 (25) |
| DBP |
82 (12) |
| HR |
76 (18) |
| BMI |
29.5 (6.7) |
| smoker |
|
| Current |
8 / 34 (24%) |
| Former |
9 / 34 (26%) |
| Never |
17 / 34 (50%) |
| previous_stroke_TIA |
|
| No Previous Stroke or TIA |
31 / 34 (91%) |
| Previous Stroke or TIA |
3 / 34 (8.8%) |
| HTN |
|
| Hypertension |
22 / 34 (65%) |
| No hypertension |
12 / 34 (35%) |
| high_chol |
|
| High cholesterol |
17 / 34 (50%) |
| Normal cholesterol |
17 / 34 (50%) |
| AF |
2 / 34 (5.9%) |
| DM |
|
| Diabetes Mellitus |
8 / 34 (24%) |
| No Diabetes Mellitus |
26 / 34 (76%) |
| IHD |
|
| History of Ischaemic Heart Disease |
4 / 34 (12%) |
| No History of Ischaemic Heart Disease |
30 / 34 (88%) |
| PVD |
|
| No peripheral vascular disease |
34 / 34 (100%) |
| FHx |
|
| Family History of Cerebrovascular Disease |
7 / 34 (21%) |
| No Family History of Cerebrovascular Disease |
27 / 34 (79%) |
| LVSD |
|
| Left Ventricular Systolic Dysfunction |
3 / 34 (8.8%) |
| No Left Ventricular Systolic Dysfunction |
31 / 34 (91%) |
| clopidogrel |
|
| No P2Y12 receptor antagonist use |
6 / 34 (18%) |
| P2Y12 receptor antagonist use |
28 / 34 (82%) |
| aspirin |
|
| Aspirin use |
19 / 34 (56%) |
| No aspirin use |
15 / 34 (44%) |
| statin |
|
| Statin use |
34 / 34 (100%) |
| anticoagulant |
|
| Anticoagulant use |
7 / 34 (21%) |
| No anticoagulant use |
27 / 34 (79%) |
| bblocker |
|
| No β-Adrenergic receptor antagonist use |
25 / 34 (74%) |
| β-Adrenergic receptor antagonist use |
9 / 34 (26%) |
| ace_arb |
|
| ACE inhibitor or ARB use |
14 / 34 (41%) |
| No ACE inhibitor or ARB use |
20 / 34 (59%) |
| diuretic |
|
| Diuretic use |
3 / 34 (8.8%) |
| No Diuretic use |
31 / 34 (91%) |
| CCB |
|
| Calcium-channel antagonist use |
8 / 26 (31%) |
| No calcium-channel antagonist use |
18 / 26 (69%) |
| Unknown |
8 |